With the use of the third-generation EGFR TKI osimertinib for patients with EGFR-mutant NSCLC with acquired resistance to first-generation TKIs, MET amplification has been reported to occur in 10%–22% of patient tumors (3–7). Here, EGFR is linked to non-small cell lung carcinoma.